In a major policy move aimed at expanding access to fertility care, President Donald Trump announced Thursday that his administration has reached a deal with pharmaceutical company EMD Serono to significantly reduce the cost of several key fertility medications.
Administration officials said the agreement is expected to help millions of Americans struggling with infertility afford the treatments they need, marking a major step toward Trump’s campaign pledge to make in vitro fertilization (IVF) and related procedures more accessible.
“In the Trump administration, we want to make it easier for couples to have babies, raise children, and start the families they’ve always dreamed of,” President Trump said during the announcement from the Oval Office.
Under the agreement, EMD Serono — one of the world’s largest fertility drug manufacturers — will offer steep discounts on its U.S. fertility medications, including Gonal-f, a widely used treatment for both men and women. The company will begin listing its discounted drugs online at what Trump described as “very, very heavily reduced prices.”
According to senior officials, the cost of fertility medications will drop between 42% and 79% per cycle, depending on a family’s income level and eligibility. The discounted drugs are slated to become available in early 2026.
Currently, fertility drugs cost an average of $5,000 to $6,000 per cycle, and only about 30% of families have access to employer-based insurance coverage for IVF treatments. The Department of Health and Human Services (HHS) reported in 2024 that a full IVF cycle typically costs between $15,000 and $20,000, with prices reaching over $30,000 if donor eggs are used.
Since patients usually require an average of 2.5 IVF cycles to conceive successfully, total treatment costs can exceed $40,000 — a price tag that has left many couples unable to pursue fertility care.
Trump’s announcement follows a series of policy initiatives designed to make reproductive medicine more affordable. In February, he signed an executive order directing federal agencies to examine ways to lower IVF costs and reduce regulatory barriers. In May, he introduced a “most favored nation” pricing policy to ensure U.S. patients pay no more for prescription drugs than consumers in other developed countries.
“This agreement delivers on the president’s pledge,” a senior official said, noting that it reflects the administration’s ongoing effort to confront inflated medical costs through direct negotiations with pharmaceutical companies.
The move has been praised by family advocacy groups, who view it as a hopeful step toward easing the financial burdens of infertility treatment — a challenge that affects roughly 1 in 6 couples worldwide.
As fertility rates continue to decline and treatment costs remain high, the Trump administration’s partnership with EMD Serono may set a precedent for future public–private collaborations aimed at improving access to reproductive healthcare.